Top PDF C myc, not HER 2/neu, can predict recurrence and mortality of patients with node negative breast cancer

C myc, not HER 2/neu, can predict recurrence and mortality of patients with node negative breast cancer

C myc, not HER 2/neu, can predict recurrence and mortality of patients with node negative breast cancer

conferred by adjuvant chemotherapy or endocrine therapy was examined in randomized studies [2,3,8,9,35–38]. Because adjuvant therapies may positively impact on outcome in only around 15%, the costs of these therapies make their routine application in all NNBC patients inap- propriate [1]. For this reason, predictive factors that accu- rately define subgroups of NNBC patients who may benefit from adjuvant systemic therapy would be a great advantage.

7 Read more

High expression of focal adhesion kinase (p125FAK) in node negative breast cancer is related to overexpression of HER 2/neu and activated Akt kinase but does not predict outcome

High expression of focal adhesion kinase (p125FAK) in node negative breast cancer is related to overexpression of HER 2/neu and activated Akt kinase but does not predict outcome

2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited. Abstract Introduction Focal adhesion kinase (FAK) regulates multiple cellular processes including growth, differentiation, adhesion, motility and apoptosis. In breast carcinoma, FAK overexpression has been linked to cancer progression but the prognostic relevance remains unknown. In particular, with regard to lymph node-negative breast cancer it is important to identify high-risk patients who would benefit from further adjuvant therapy.
Show more

10 Read more

Prevalence of HER-2/ neu receptor amplification and its effects over prognosis of the patients with breast cancer

Prevalence of HER-2/ neu receptor amplification and its effects over prognosis of the patients with breast cancer

was associated with Comedo carcinoma variant. 3-5 Later in subsequent studies HER-2/neu protein expression associated with breast cancers has been confirmed., further evaluation of this receptor appear warranted to confirm whether this marker can be clinically useful in stratifying patients into low risk groups, which may be followed conservatively, and high risk groups that may require extensive post biopsy surgical procedures to prevent recurrence and to rule out invasive disease with an aggressive phenotype. 6-7 HER-2 /neu gene expression has generally not been specifically implicated in progression or prognosis assessment of lobular carcinoma of breast, but it is strongly associated with increased disease recurrence and a poor prognosis. 8 Over expression is also known to occur in ovarian, stomach, and aggressive forms of uterine cancer. 9 Multiple studies reported a significant co-relation of serum HER-2/neu protein levels with recurrence, metastasis or shortened survival. It also predicts the resistance of breast cancer to chemotherapy and absence of clinical response to hormonal therapy even when estrogen assays are positive. 10 Hence it is concluded that HER-2/neu amplification is an independent predictor of shorter disease with free survival in both node negative node and positive note patients. 11
Show more

5 Read more

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

We used a multistep approach to develop an as- say of the expression of tumor-related genes for use with routinely prepared tumor blocks and to val- idate the assay clinically. First, a high-throughput, real-time, reverse-transcriptase–polymerase-chain- reaction (RT-PCR) method was developed to quanti- fy gene expression with the use of sections of fixed, paraffin-embedded tumor tissue. 22 Second, we se- lected 250 candidate genes from the published lit- erature, genomic databases, and experiments based on DNA arrays performed on fresh-frozen tis- sue. 17-19,23 Third, we analyzed data from three inde- pendent clinical studies of breast cancer involving a total of 447 patients, including the tamoxifen-only group of NSABP trial B-20, to test the relation be- tween expression of the 250 candidate genes and the recurrence of breast cancer. 24-26 Fourth, we used the results of the three studies to select a panel of 16 cancer-related genes and 5 reference genes and de- signed an algorithm, based on the levels of expres- sion of these genes, to compute a recurrence score for each tumor sample. The study reported here was performed to validate the ability of the prospective-
Show more

10 Read more

HER 2 therapy  HER 2/neu diagnostics in breast cancer

HER 2 therapy HER 2/neu diagnostics in breast cancer

Before the decision by the FDA to clear the serum HER-2/ neu test with a standardized cutpoint of 15 ng/ml, many reports used different research assays with various, uncharacterized antibody specificities, calibrators, and cutoff values to measure circulating HER-2/neu level. For instance, in a previous review [18] it was shown that there were 21 references to the Triton-Ciba-Chiron HER-2/neu assay but 11 different cutoffs, ranging from 5 to 30 units/ml or from 120 or 450 fmol/ml. We found five references to the Nicherei assay, three references to the Calbiochem or the Oncogene Research Products assay, three references to the Dianova assay, and two references to the Bender assay. We could not find any references that described antibody specificities or standardization of these assays, and neither were the findings compared with standardized results. All of the assays mentioned above were available for research use only, which means that the performance characteristics of the assay had not been determined. Unlike FDA-cleared in vitro diagnostic products, there are no manufacturing guidelines for research use only products, which often results in inconsistent findings.
Show more

11 Read more

Long term prognostic significance of HER 2/neu in untreated node negative breast cancer depends on the method of testing

Long term prognostic significance of HER 2/neu in untreated node negative breast cancer depends on the method of testing

These apparent discrepancies have largely prevented the widespread acceptance of HER-2/neu as a prognostic fac- tor in node-negative breast cancer up to now [36]. Several possible reasons could account for these contro- versial findings. One frequently quoted, simple but none- theless unsatisfactory reason could be the rather small sample size of several studies. However, a strong and bio- logically relevant prognostic factor should eventually become evident even within a small sample size. Another possible reason is the remarkable discrepancy in sensitivity between the numerous antibodies used [16] and differ- ences in tissue fixation and processing [37]. However, per- haps the most important reason is the lack of a standardised evaluation protocol in many of the older stud- ies. The standardisation of IHC has become increasingly important since the successful use of trastuzumab (Her- ceptin™) in the treatment of HER-2/neu-overexpressing metastatic breast cancer [17,20,38]. The United States Food and Drug Administration has approved a standard-
Show more

11 Read more

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women

Previous studies in Western countries show that TN breast cancer has aggressive clinical and pathologic features, including onset at a young age, advanced stage at diagnosis, high histopathologic and nuclear grade, high mitotic index, higher frequency of unfavorable histopathology, and more distant recurrence. 8–11 In addition, evidence indicates that the prevalence and clinical outcomes of TN breast cancer dif- fer among races. 11 Bauer et al 8 have reported that TN breast cancer is more prevalent among non-Hispanic black women compared with other ethnic groups, who when affected with this subtype had the worst survival. Carey et al 11 also reported that basal-like breast tumors occurred at a higher prevalence among African American women compared with other racial groups. However, there are limited studies of the prevalence, characteristics, and prognosis of TN breast cancer in Asian populations. A recent study of Korean patients indicated that the basal-like subtype, which is positive for one or more of the basal markers and negative for HRs and HER-2/neu, was not associated with a poor prognosis. This study also showed that the survival rate associated with the basal-like subtype does not differ from that of other subtypes, with the exception of the HER2/neu-overexpressing subtype, which has the worst survival rate. 12 In contrast, a recent study of breast cancer patients receiving neoadjuvant chemotherapy showed that TN breast cancer was associated with shorter survival than other subtypes, even though it was associated with a higher response rate. 13
Show more

11 Read more

Tumor escape and progression of HER 2/neu negative breast cancer under immune pressure

Tumor escape and progression of HER 2/neu negative breast cancer under immune pressure

nuclear staining along with cytosolic staining for IFN-g Ra in their tumors. Discussion If HER-2/neu-specific IFN-g producing T cells are involved in HER-2/neu loss and tumor recurrence, we might be able to detect such immune responses in patients with HER-2/neu negative breast cancer, who might have had undetectable HER-2/neu positive pre- malignant tumors in the past, that had lost HER-2/neu expression and progressed to invasive carcinoma under the immune pressure. The fact that 55-75% of patients with premalignant DCIS overexpress HER-2/neu in their tumor lesions and 75% of breast cancers are HER-2/neu negative would suggest the progression of HER-2/neu positive DCIS to HER-2/neu negative breast cancer is only in the tumor clones that express IFN-g Ra. We have already shown that T cell-mediated tumor antigen loss was due to hypermethylation of the neu promoter and loss of neu both at mRNA and protein levels [3,5].
Show more

5 Read more

Cancer biomarker HER-2/neu in breast cancer in Indian women

Cancer biomarker HER-2/neu in breast cancer in Indian women

neu protein, such as the tyrosine kinase inhibitor lapatinib, which appears to have clinical activity after failure of tras- tuzumab therapy. 24 Tumors, including metastatic lesions, shed large numbers of tumor cells into the blood circulation, and the presence of circulating tumor cells is of biologic relevance in the metastatic setting. Based on the hypothesis that the pheno- type of circulating tumor cells may reflect the phenotype of metastatic disease, characterization of circulating tumor cells may be useful for reassessment of HER-2/neu status and additional therapeutic cancer biomarkers. However, this option is limited to those patients with detectable circulating tumor cells. Reported positivity rates for circulating tumor cells in metastatic breast cancer patients range from 20%
Show more

6 Read more

Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer

Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer

The HER-2/neu (also known as ERBB2) proto-oncogene, which encodes a trans- membrane growth factor receptor with tyrosine kinase activity, has become an important subject for human cancer re- search during the last decade. The impact of HER-2 amplification and expression on prognosis (1–12) and on the response to cytotoxic (4,13–18) and hormonal (15,19–22) therapies in breast cancer patients have been studied intensively. Studies of HER-2 represent a paradigm of how genetic findings have led to the development of a gene-specific therapy: In September 1998, the U.S. Food and Drug Administration approved trastuzamab (Herceptin), a recombinant monoclonal antibody targeting Her-2, for the treat- ment of metastatic breast cancer. Al- though trastuzumab binds to the Her-2 receptor with high affinity, the mecha- nism of action by which it causes tumor reduction is not understood. Despite the theoretic benefits of such a targeted treat- ment, not all patients respond favorably to trastuzamab treatment in practice. Among the patients with HER-2-positive meta- static breast cancer that is resistant to con- ventional cytotoxic treatment, only about 25% benefit from trastuzamab given in combination with cisplatin (23). The ge- netic features that distinguish the HER-2- positive breast cancers that respond to trastuzamab from those that do not remain unclear. However, it is possible that the extent of HER-2 amplification and/or overexpression in the primary tumor dif- fers from that in the metastases. The HER-2 status of the primary tumor, which is removed from the patient, determines whether or not trastuzamab treatment is prescribed. But trastuzamab works by tar- geting the metastases that remain in the patient. If at least some of the multiple metastases of an HER-2-positive primary breast tumor did not express HER-2, trastuzamab treatment would most likely not affect the course of the disease. A comprehensive, large-scale study compar- ing HER-2 gene copy numbers and pro- tein expression in primary tumors and in multiple different metastases derived from them has not been performed. To gain insight into the patterns of HER-2
Show more

6 Read more

Immunization with a HER 2/neu helper peptide vaccine generates HER 2/neu CD8 T cell immunity in cancer patients

Immunization with a HER 2/neu helper peptide vaccine generates HER 2/neu CD8 T cell immunity in cancer patients

Received for publication November 10, 2000, and accepted in revised form January 3, 2001. CD4 T-cell help is required during the generation and maintenance of effective antitumor CD8 T cell–mediated immunity. The goal of this study was to determine whether HER-2/neu–specific CD8 T-cell immunity could be elicited using HER-2/neu–derived MHC class II “helper” peptides, which contain encompassed HLA-A2–binding motifs. Nineteen HLA-A2 patients with HER-2/neu–overex- pressing cancers received a vaccine preparation consisting of putative HER-2/neu helper peptides p369–384, p688–703, and p971–984. Contained within these sequences are the HLA-A2–binding motifs p369–377, p689–697, and p971–979. After vaccination, the mean peptide-specific T-cell pre- cursor frequency to the HLA-A2 peptides increased in the majority of patients. In addition, the pep- tide-specific T cells were able to lyse tumors. The responses were long-lived and detectable for more than 1 year after the final vaccination in select patients. These results demonstrate that HER-2/neu MHC class II epitopes containing encompassed MHC class I epitopes are able to induce long-lasting HER-2–specific IFN-γ–producing CD8 T cells.
Show more

9 Read more

Exposure to depleted uranium does not alter the co expression of HER 2/neu and p53 in breast cancer patients

Exposure to depleted uranium does not alter the co expression of HER 2/neu and p53 in breast cancer patients

Conclusion In conclusion, the positive expression of these biomar- kers is associated with biologically aggressive tumors and poor prognostic profile. Although the samples were taken from an area where the exposure to depleted ura- nium is a risk, the incidence of co-expression of both p53 and HER-2/neu markers does not differ from simi- lar cancer samples in areas that have not been exposed to depleted uranium, though, the greater immunoex- pression of Her-2/neu in breast cancer in this popula- tion with risk for DU exposure, compared with findings on other populations not at risk, requires further inves- tigation as it may reflect the possible role of DU in the induction or acceleration of network signaling between different Her-2 receptors. New lines of treatment which includes genetic modulation of the signaling pathway of both genes should be considered in patients’ medical follow up. Unfortunately for DU, knowledge of the exposure time, dose absorbed, route, length of exposure and its health consequences on the Iraqi population is still lacking. This is chiefly due to restricted access of scientists required to conduct such study and should form the basis for future investigations.
Show more

8 Read more

Excess of cardiovascular mortality among node-negative breast cancer patients irradiated for inner-quadrant tumors

Excess of cardiovascular mortality among node-negative breast cancer patients irradiated for inner-quadrant tumors

statistical analysis Using chi-square test for heterogeneity (for categorical variables) and Fisher exact t-test (for continuous variables), we compared patient and tumor characteristics and treatment. We compared cardiovascular, breast cancer- specific, and overall mortality between patients with left- versus right-sided breast cancer and with inner-quadrant versus outer-quadrant breast cancer by log-rank tests and by Cox regressions. To evaluate the independent effect of breast cancer laterality, we adjusted mortality risk for variables associated to laterality and cardiovascular disease, breast cancer-specific or overall mortality, respectively. To asses the effect of breast quadrants on mortality risks, we adjusted for factors associated to breast quadrants, cardiovascular disease, breast cancer-specific or overall mortality, respectively. As ER status and tamoxifen use were highly correlated, we adjusted only for ER status. In order to examine if the effect of irradiation linked to quadrant on cardiovascular mortality differed across age group, type of surgery, use of chemotherapy, use of hormonal therapy, and laterality, we carried out interaction tests. Interaction terms involved quadrant (inner, outer) and age group (<50, ‡50), surgery (breast-conserving surgery, mastectomy), chemotherapy (yes, no), hormonal therapy (yes, no), or laterality (left, right). We also carried out separate analyses to assess the differences in the use of internal mammary lymph node chain irradiation and in the dose of the boost. We considered the following three categories: high level of IMC irradiation and low boost dose (1980–1987), high-level IMC and high boost dose (1988–1990), and low IMC and high boost dose (1991–2004).
Show more

7 Read more

HER-2/Neu over-expression in invasive Bladder Cancer in Sudanese Patients

HER-2/Neu over-expression in invasive Bladder Cancer in Sudanese Patients

Abstract: Background: Bladder cancer is one of the commonest malignancies with high morbidity and mortality rates. Human Epidermal Growth Factor Receptor -2 (Her-2/Neu) seems to play role in the pathogenesis and prognosis of bladder carcinomas; However it is expression and prognostic significance were variable between different studies.

10 Read more

DNA methylation markers predict recurrence-free interval in triple-negative breast cancer

DNA methylation markers predict recurrence-free interval in triple-negative breast cancer

our diverse cohorts, including in the chemotherapy arms of our institutional samples and IBCSG trial samples. In summary, our fi nding of a repeated association between methylation patterns and long-term outcome suggest that further exploration of their potential to better risk-stratify patients in well- characterized TNBC datasets may be warranted. We have identi fi ed patterns of methylation that are associated with prognosis among patients with TNBC, although they are at present not predictive of response to local-regional or systemic therapy. While these fi ndings cannot be exploited to improve clinical decision making today, our results, and the underlying data, collected on an increasingly rare group of TNBC patients treated with locoregional therapy alone, are a valuable contribu- tion to ongoing research on the development, progression and ultimate treatment of TNBC.
Show more

6 Read more

Original Article Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population

Original Article Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population

Significant differences were found in vascular invasion, grade and molecular subtype between the two groups. Expression of ER and PR in the ‘poor group’ was lower (P < 0.05). However, positive rates of Ki67, p53 and VEGF in the ‘poor group’ were higher (P < 0.05). Multivariate analysis revealed that molecular subtype, expression of VEGF, tumor grade, and vascular invasion were closely correlated with bad outcome. Analysis of the ‘poor group’ demon- strated that ‘HER2 positive’ and ‘triple negative’ subtypes more commonly suffered from distant metastases and death. No metastasis was found in patients with pure invasive papillary carcinoma, invasive cribriform carcinoma or adenoid cystic carcinoma, whereas the diagnoses of invasive micropapillary carcinoma, invasive apocrine carci- noma, invasive papillary carcinoma mixed with invasive ductal carcinoma, or metaplastic carcinoma were correlated with distant metastasis and death. In conclusion, molecular subtype and expression of VEGF are useful markers for predicting prognosis of ANN breast cancer patients. ‘Luminal A-like’ subtype has better outcome than others.
Show more

11 Read more

Keywords HER-2 Steroid receptors Lymph node Breast cancer. Introduction

Keywords HER-2 Steroid receptors Lymph node Breast cancer. Introduction

currently not mature enough to report and will also reflect the predictive value of different treatment modalities in different receptor subgroups. Another potential weakness of our report may be that we based the ALN status on results from a mixture of complete axillary node dissection and sentinel lymph node procedure. However, it has previously been shown that predictors for ALN status are independent of how the lymph node resection was performed although the metastatic detection rate in lymph nodes may be higher using the sentinel node procedure as more thorough histo- logic examination of the sentinel lymph node results in a higher number of metastases detected [31]. Another weak- ness may be that we did not consider other predictors for ALN status as tumour localisation within the breast, tumour vascularisation, lymphangiogenesis, protein and genetic markers for ALN involvement [32]. Another important information which is missing is whether triple positive breast cancers, apart from being more likely lymph node positive, also involved a higher number of lymph nodes as compared to breast cancers with a non-triple positive phe- notype. Such information may strengthen our findings. A strength of our study is that cases were unselected and consecutively treated in one centre. Also, analyses for ER, PR and HER-2 were confirmed by one pathologist. Suc- cessful quality control and quality assurance programs were guaranteed in our laboratory according to requested guidelines. Another strength of our study is that we defined HER-2 + on the base of membrane staining when they either had a DAKO score 3 + or 2 + with a positive FISH test.
Show more

7 Read more

Risk of Regional Recurrence After Negative Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence

Risk of Regional Recurrence After Negative Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence

Only the 1% of patients with ipsilateral axillary recur- rence after rSLNB could have had a possible benefit from ALND. The other seven (3.5%) regional recurrences were found outside the ipsilateral axilla. These aberrant sites of recurrence were in concordance with the site of the har- vested rSLNB in three cases. For these patients, the histologic outcome of rSLNB was possibly false negative. In four other patients, the regional recurrence was not concordant with the location of the rSLNB. One explana- tion could be that rSLNB in IBTR is a technically challenging procedure. As published before, injection with a larger amount of tracer leads to a higher identification rate. 32 In this study, patients with regional recurrence had a significantly lower amount of tracer injected. Injection of a higher tracer dose might have led to identification of repeat sentinel lymph nodes in additional basins. It could also be hypothesized that lymph drainage of the IBTR might have been multidirectional, and the rSLNB identified only one basin.
Show more

11 Read more

Clinical outcomes after sentinellymph node biopsy in clinically node-negative breast cancer patients

Clinical outcomes after sentinellymph node biopsy in clinically node-negative breast cancer patients

In early breast cancer patients with negative SLN, no further ALND is recommended. In the case of sentinel node metastasis, most clinical practice guidelines recommend complete ALND. Although additional ALN involvement was found in 35%–60% of positive SLN patients, the axillary recurrence rate is reported to be 0.2%–0.9% for micrometastatic disease of SLN and around 1% for macrometastatic disease [9,12-15]. Based on these results, the hypothesis that ALN metastatic disease does not cause regional recurrence has been accepted. Therefore, several randomized phase 3 trials have been performed to investigate whether ALND can safely be omitted in early breast cancer patients with positive SLN. In the American College of Surgeons Oncology Group Z0011 trial, clinically node-negative early breast cancer patients with positive SLN were randomized to ALND or no ALND groups. At the median follow-up of 6.3 years, no difference was observed between groups for OS, progression-free survival (PFS) or locoregional PFS. The International Breast Cancer Study Group trial 23-01 trial was designed to determine whether no ALND was inferior to ALND in patients with one or more micrometastatic SLN with a tumor of maximum 5 cm. After a median follow-up of 5 years, no difference was found between the ALND and no ALND groups for OS or PFS. In both trials, axillary recurrence in the no ALND group was about 1%. In the AMAROS trial, ALND and axillary radiotherapy were compared. After a follow-up of 5 years, axillary radiotherapy was equivalent to ALND in OS, PFS, and axillary recurrence [7,9,16].
Show more

6 Read more

Practice patterns and outcomes for patients with node negative hormone receptor positive breast cancer and intermediate 21 gene Recurrence Scores

Practice patterns and outcomes for patients with node negative hormone receptor positive breast cancer and intermediate 21 gene Recurrence Scores

Our study documents the practice patterns of chemo- therapy use in this select population of breast cancer patients, and highlights the importance of the Oncotype DX Recurrence Score in influencing treatment recom- mendations. Individualized medicine involves separating patients into specific subsets using scientific knowledge to identify meaningful parameters. The establishment of the Low, Intermediate, and High Risk groups by the Oncotype DX score is an important step in this direction. These types of tests provide more clarity for patients and health- care providers, reduce overtreatment, and potentially re- duce healthcare costs. The application of the Recurrence Score has been modeled to be an economically advanta- geous clinical tool, possibly saving over $1000 per patient [11, 24]. Further partitioning of Low, Intermediate, and High Risk groups of patients will optimize therapy for each individual.
Show more

13 Read more

Show all 10000 documents...